
IRLAB Q4 2023 - FDA meeting closing in

Redeye updates its view of IRLAB following the Q4 report and largely reiterate our previous view. We think that the next significant trigger is the outcome of the end-of-phase II meeting on Mesdopetam, news on business development/financing and trial initiation of the IRL757 phase I trial.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release

Attachments

[IRLAB Q4 2023 - FDA meeting closing in](#)